Page 225 - Genentech News Today

As the No. 2 large company on the 2023 Best Places to Work in IT list, the biotech company has a focus on wellness that starts with creating a supportive work environment.

Workplace flexibility, diversity, and opportunity prevail at the top employers in our 29th annual Best Places to Work in IT report.

DUBLIN--(BUSINESS WIRE)--The "2023 Controlled & Modified Drug Release Summit" conference has been added to ResearchAndMarkets.com's offering.The next generation of drug and therapeutic delivery is here.Attend and connect with 160+ senior drug development innovators this May and uncover the industry's latest formulat...

This report, the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)–Outcomes 2022 extension, is a consensus statement on the standards

– US board-certified medical oncologist with extensive global clinical and regulatory experience advancing oncology medicines from early development stages...

"The study provides a rich platform for additional translational research to evaluate more sensitive methods of HER2 detection."

Updated data from the phase III POLARIX study continue to demonstrate a statistically significant reduction in the risk of disease worsening or death for people with previously untreated diffuse large

A three-drug combination that sent chronic lymphocytic leukemia (CLL) into deep remissions in a broad group of patients in a clinical trial is highly effective in patients with high-risk forms of the disease, a new, phase 2 clinical trial led by Dana-Farber Cancer Institute investigators indicates.

BioPharma

Data showcase the potential of glofitamab and Lunsumio to address diverse patient needsData presented at ASH 2022 and simultaneously published in the New England Journal of Medicine showed that glofitamab